Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.
- Author(s): Ellingson, Benjamin M
- Wen, Patrick Y
- Cloughesy, Timothy F
- et al.
Published Web Locationhttps://doi.org/10.1093/neuonc/nox193
The use of contrast enhancement within the brain on CT or MRI has been the gold standard for diagnosis and therapeutic response assessment in malignant gliomas for decades. The use of contrast enhancing tumor size, however, remains controversial as a tool for accurately diagnosing and assessing treatment efficacy in malignant gliomas, particularly in the current, quickly evolving therapeutic landscape. The current article consolidates overwhelming evidence from hundreds of studies in the field of neuro-oncology, providing the necessary evidence base and specific contexts of use for consideration of contrast enhancing tumor size as an appropriate surrogate biomarker for disease burden and as a tool for measuring treatment response in malignant glioma, including glioblastoma.